Tokyo, Nov. 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063577) titled 'Real-world clinical data of geographic atrophy with or without treatments with avacincaptad pegol in Japan' on Nov. 13.
Study Type:
Observational
Primary Sponsor:
Institute - Fujita Medical Innovation Center, Tokyo
Condition:
Condition - age-related macular degeneration with geographic atrophy
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - We analyze clinical courses of the patients diagnosed with age-related macular degeneration with geographic atrophy with or without izervay treatment and show the safety and efficacy of the treatment.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - Those who exhibit geographic atrophy secondary to age-related macular degeneration
Key exclusion criteria - 1.Those who do not agree to participate the study
2.Those whoes data are not clear
3.Those who exhibit atrophic lesions due to pathologic myopia or inherited retinal diseases
Target Size - 80
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2026 Year 08 Month 17 Day
Date of IRB - 2026 Year 08 Month 17 Day
Anticipated trial start date - 2026 Year 11 Month 14 Day
Last follow-up date - 2030 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072755
Disclaimer: Curated by HT Syndication.
